{
    "PMC8668943_3": [
        {
            "subject": {
                "gene": "FCGR2C",
                "region": "CNR1",
                "outcome": "perinatal HIV-1 acquisition",
                "adjustment factors": "birthweight and FCGR2C genotypes",
                "copy number": "1"
            },
            "measures": "[univariate OR, 95% CI, P-value, P_Bonf, adjusted OR, adjusted P-value, adjusted P_Bonf]",
            "outcomes": "[0.29, 0.12-0.71, 0.007, 0.112, 0.37, 0.029, 0.464]"
        },
        {
            "subject": {
                "gene": "FCGR2C",
                "region": "CNR1",
                "outcome": "perinatal HIV-1 acquisition",
                "adjustment factors": "birthweight and FCGR2C genotypes",
                "copy number": "2",
                "reference": "yes"
            },
            "measures": "[univariate OR, 95% CI, P-value, P_Bonf, adjusted OR, adjusted P-value, adjusted P_Bonf]",
            "outcomes": "[Ref, , , , Ref, , ]"
        },
        {
            "subject": {
                "gene": "FCGR2C",
                "region": "CNR1",
                "outcome": "perinatal HIV-1 acquisition",
                "adjustment factors": "birthweight and FCGR2C genotypes",
                "copy number": "\u22653"
            },
            "measures": "[univariate OR, 95% CI, P-value, adjusted OR, adjusted P-value]",
            "outcomes": "[0.99, 0.63-1.57, 0.978, 0.74, 0.275]"
        }
    ],
    "PMC5817808_2": [
        {
            "subject": {
                "analysis": "survival at 24 months",
                "population": "HIV exposed infants",
                "location": "Essos hospital center PMTCT program",
                "test": "Global Schoenfeld residuals test",
                "adjustment": "adjusted"
            },
            "measures": "[p-value]",
            "outcomes": "[0.23]"
        }
    ],
    "PMC5574138_3": [
        {
            "subject": {
                "analysis": "meta-regression",
                "dependent variable": "not specified",
                "covariate": "Length of follow-up",
                "statistical representation": "estimate"
            },
            "measures": "[estimate, S.E, 95% CI]",
            "outcomes": "[-0.0138, 0.0666, (-0.1322-0.1046)]"
        },
        {
            "subject": {
                "analysis": "meta-regression",
                "dependent variable": "not specified",
                "covariate": "Median CD4 count",
                "statistical representation": "estimate"
            },
            "measures": "[estimate, S.E, 95% CI]",
            "outcomes": "[-0.0034, 0.0066, (-0.0150-0.0079)]"
        },
        {
            "subject": {
                "analysis": "meta-regression",
                "dependent variable": "not specified",
                "covariate": "Median age",
                "statistical representation": "estimate"
            },
            "measures": "[estimate, S.E, 95% CI]",
            "outcomes": "[0.0415, 0.0503, (-0.1013-0.0755)]"
        },
        {
            "subject": {
                "analysis": "meta-regression",
                "dependent variable": "not specified",
                "covariate": "Year of publication",
                "statistical representation": "estimate"
            },
            "measures": "[estimate, S.E, 95% CI]",
            "outcomes": "[0.0637, 0.0815, (-0.1736-0.0980)]"
        },
        {
            "subject": {
                "analysis": "meta-regression",
                "dependent variable": "not specified",
                "covariate": "Female proportion",
                "statistical representation": "estimate"
            },
            "measures": "[estimate, S.E, 95% CI]",
            "outcomes": "[-0.5305, 1.4575, (-3.6792-2.6183)]"
        }
    ],
    "PMC4794224_2": [
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "gene": "KIR2DL1"
            },
            "measures": "[N, % Positive]",
            "outcomes": "[966, 97%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "gene": "KIR2DL3"
            },
            "measures": "[N, % Positive]",
            "outcomes": "[719, 72%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "gene": "KIR2DL4"
            },
            "measures": "[N, % Positive]",
            "outcomes": "[993, 100%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "gene": "KIR2DL5"
            },
            "measures": "[N, % Positive]",
            "outcomes": "[547, 55%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "gene": "KIR2DL2*004"
            },
            "measures": "[N, % Positive]",
            "outcomes": "[31, 3%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "gene": "KIR2DL2*001/2/3/5"
            },
            "measures": "[N, % Positive]",
            "outcomes": "[544, 55%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "gene": "KIR2DP1"
            },
            "measures": "[N, % Positive]",
            "outcomes": "[964, 97%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "gene": "KIR2DS1"
            },
            "measures": "[N, % Positive]",
            "outcomes": "[548, 55%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "gene": "KIR2DS2"
            },
            "measures": "[N, % Positive]",
            "outcomes": "[581, 59%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "gene": "KIR2DS3"
            },
            "measures": "[N, % Positive]",
            "outcomes": "[401, 40%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "gene": "KIR2DS4"
            },
            "measures": "[N, % Positive]",
            "outcomes": "[993, 100%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "gene": "KIR2DS5"
            },
            "measures": "[N, % Positive]",
            "outcomes": "[281, 28%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "gene": "KIR3DL1"
            },
            "measures": "[N, % Positive]",
            "outcomes": "[929, 94%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "gene": "KIR3DL2"
            },
            "measures": "[N, % Positive]",
            "outcomes": "[993, 100%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "gene": "KIR3DL3"
            },
            "measures": "[N, % Positive]",
            "outcomes": "[993, 100%]"
        },
        {
            "subject": {
                "analysis": "Frequency of KIR alleles",
                "gene": "KIR3DS1"
            },
            "measures": "[N, % Positive]",
            "outcomes": "[354, 36%]"
        }
    ],
    "PMC9077443_2": [
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Overall",
                "treatment": "cabotegravir",
                "events": "4",
                "total person-years": "1956",
                "comparison": "TDF-FTC"
            },
            "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
            "outcomes": "[0.20%, 0.12 (0.05\u20130.31), <0.0001]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Overall",
                "treatment": "TDF-FTC",
                "events": "36",
                "total person-years": "1942",
                "comparison": "cabotegravir"
            },
            "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
            "outcomes": "[1.85%, 0.12 (0.05\u20130.31), <0.0001]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Age <25 years",
                "treatment": "cabotegravir",
                "events": "3",
                "total person-years": "866",
                "comparison": "TDF-FTC"
            },
            "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
            "outcomes": "[0.35%, 0.17 (0.05\u20130.54), 0.53]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Age <25 years",
                "treatment": "TDF-FTC",
                "events": "20",
                "total person-years": "851",
                "comparison": "cabotegravir"
            },
            "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
            "outcomes": "[2.34%, 0.17 (0.05\u20130.54), 0.53]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Age \u226525 years",
                "treatment": "cabotegravir",
                "events": "1",
                "total person-years": "1090",
                "comparison": "TDF-FTC"
            },
            "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
            "outcomes": "[0.09%, 0.09 (0.02\u20130.49), 0.53]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Age \u226525 years",
                "treatment": "TDF-FTC",
                "events": "16",
                "total person-years": "1091",
                "comparison": "cabotegravir"
            },
            "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
            "outcomes": "[1.47%, 0.09 (0.02\u20130.49), 0.53]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Contraceptive method DMPA",
                "treatment": "cabotegravir",
                "events": "3",
                "total person-years": "1009",
                "comparison": "TDF-FTC"
            },
            "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
            "outcomes": "[0.30%, 0.16 (0.05\u20130.53), 0.87]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Contraceptive method DMPA",
                "treatment": "TDF-FTC",
                "events": "21",
                "total person-years": "1000",
                "comparison": "cabotegravir"
            },
            "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
            "outcomes": "[2.10%, 0.16 (0.05\u20130.53), 0.87]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Contraceptive method NET-EN",
                "treatment": "cabotegravir",
                "events": "1",
                "total person-years": "175",
                "comparison": "TDF-FTC"
            },
            "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
            "outcomes": "[0.57%, 0.22 (0.03\u20131.48), 0.87]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Contraceptive method NET-EN",
                "treatment": "TDF-FTC",
                "events": "6",
                "total person-years": "182",
                "comparison": "cabotegravir"
            },
            "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
            "outcomes": "[3.30%, 0.22 (0.03\u20131.48), 0.87]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Contraceptive method Implant",
                "treatment": "cabotegravir",
                "events": "0",
                "total person-years": "not specified",
                "comparison": "TDF-FTC"
            },
            "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
            "outcomes": "[0%, 0.06 (0.00\u20131.16), 0.87]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Contraceptive method Implant",
                "treatment": "TDF-FTC",
                "events": "8",
                "total person-years": "607",
                "comparison": "cabotegravir"
            },
            "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
            "outcomes": "[1.32%, 0.06 (0.00\u20131.16), 0.87]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Contraceptive method Other",
                "treatment": "cabotegravir",
                "events": "0",
                "total person-years": "not specified",
                "comparison": "TDF-FTC"
            },
            "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
            "outcomes": "[0%, 0.32 (0.01\u20139.89), 0.87]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Contraceptive method Other",
                "treatment": "TDF-FTC",
                "events": "1",
                "total person-years": "152",
                "comparison": "cabotegravir"
            },
            "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
            "outcomes": "[0.66%, 0.32 (0.01\u20139.89), 0.87]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Body-mass index \u226430 kg/m2",
                "treatment": "cabotegravir",
                "events": "4",
                "total person-years": "1389",
                "comparison": "TDF-FTC"
            },
            "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
            "outcomes": "[0.29%, 0.16 (0.06\u20130.45), 0.47]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Body-mass index \u226430 kg/m2",
                "treatment": "TDF-FTC",
                "events": "27",
                "total person-years": "1447",
                "comparison": "cabotegravir"
            },
            "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
            "outcomes": "[1.87%, 0.16 (0.06\u20130.45), 0.47]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Body-mass index >30 kg/m2",
                "treatment": "cabotegravir",
                "events": "0",
                "total person-years": "not specified",
                "comparison": "TDF-FTC"
            },
            "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
            "outcomes": "[0%, 0.05 (0.00\u20130.96), 0.47]"
        },
        {
            "subject": {
                "analysis": "Cabotegravir effectiveness",
                "group": "Body-mass index >30 kg/m2",
                "treatment": "TDF-FTC",
                "events": "9",
                "total person-years": "495",
                "comparison": "cabotegravir"
            },
            "measures": "[HIV incidence per 100 person-years, HR (95% CI), p value]",
            "outcomes": "[1.82%, 0.05 (0.00\u20130.96), 0.47]"
        }
    ],
    "PMC10294491_2": [
        {
            "subject": {
                "trial": "DISCOVER",
                "group": "TDF/FTC",
                "analysis type": "Original analysis on rate ratio scale",
                "subjects": "2693",
                "PYFU": "4386",
                "reference": "REF"
            },
            "measures": "[incident HIV infections, incidence rate (per 100 PYFU), rate ratio (95% CI)]",
            "outcomes": "[11, 0.251, REF]"
        },
        {
            "subject": {
                "trial": "DISCOVER",
                "group": "TAF/FTC",
                "analysis type": "Original analysis on rate ratio scale",
                "subjects": "2694",
                "PYFU": "4370"
            },
            "measures": "[incident HIV infections, incidence rate (per 100 PYFU), rate ratio (95% CI)]",
            "outcomes": "[6, 0.137, 0.55 (0.20, 1.48)]"
        },
        {
            "subject": {
                "trial": "DISCOVER",
                "group": "TDF/FTC",
                "analysis type": "Re-analysis using an averted infections framework",
                "PYFU": "4386",
                "reference": "REF"
            },
            "measures": "[observed infections, predicted infections, averted infections, averted infections ratio (95% CI)]",
            "outcomes": "[11, 90.4, 79.4, REF]"
        },
        {
            "subject": {
                "trial": "DISCOVER",
                "group": "TAF/FTC",
                "analysis type": "Re-analysis using an averted infections framework",
                "PYFU": "4370"
            },
            "measures": "[observed infections, predicted infections, averted infections, averted infections ratio (95% CI)]",
            "outcomes": "[6, 90.0, 84.0, 1.06 (0.96\u20131.17)]"
        },
        {
            "subject": {
                "trial": "DISCOVER",
                "analysis type": "Re-analysis using an averted infections framework",
                "predicted infections calculation": "Applying counterfactual placebo incidence rate of 2.06 per 100 PYFU (lower 2.5% credibility limit)"
            }
        },
        {
            "subject": {
                "trial": "DISCOVER",
                "expected endpoints per arm": "72",
                "observed HIV incidence": "much lower than expected"
            }
        }
    ],
    "PMC6158807_3": [
        {
            "subject": {
                "endpoint": "composite endpoint",
                "total events": "692",
                "number of events": "123",
                "person-years of follow-up": "4071"
            },
            "measures": "[rate per 100 person-years, 95% CI]",
            "outcomes": "[3.02, 2.53\u20133.61]"
        },
        {
            "subject": {
                "endpoint": "composite endpoint",
                "current CD4/CD8 ratio": "< 0.3",
                "number of events": "21",
                "person-years of follow-up": "184"
            },
            "measures": "[rate per 100 person-years, 95% CI]",
            "outcomes": "[11.42, 7.45\u201317.52]"
        },
        {
            "subject": {
                "endpoint": "composite endpoint",
                "current CD4/CD8 ratio": "0.30\u20130.45",
                "number of events": "28",
                "person-years of follow-up": "496"
            },
            "measures": "[rate per 100 person-years, 95% CI]",
            "outcomes": "[5.64, 3.90\u20138.17]"
        },
        {
            "subject": {
                "endpoint": "composite endpoint",
                "current CD4/CD8 ratio": "> 0.45",
                "number of events": "72",
                "person-years of follow-up": "3227"
            },
            "measures": "[rate per 100 person-years, 95% CI]",
            "outcomes": "[2.23, 1.77\u20132.81]"
        },
        {
            "subject": {
                "endpoint": "composite endpoint",
                "statistical test": "long rank test",
                "p-value": "< 0.001"
            }
        }
    ],
    "PMC7522205_2": [
        {
            "subject": {
                "study_type": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                "population": "newly diagnosed HIV patients",
                "total_patients": "2845",
                "total_percentage": "100.0",
                "total_cd4_median": "160",
                "total_cd4_iqr_lower": "49",
                "total_cd4_iqr_upper": "310"
            },
            "measures": "[CD4+ median, CD4+ IQR lower, CD4+ IQR upper]",
            "outcomes": "[160, 49, 310]"
        },
        {
            "subject": {
                "study_type": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                "population": "newly diagnosed HIV patients",
                "hiv1_genotype": "CRF01_AE",
                "patients": "1687",
                "percentage": "59.3",
                "cd4_median": "111",
                "cd4_iqr_lower": "31",
                "cd4_iqr_upper": "279",
                "unadjusted_coefficient": "0",
                "adjusted_coefficient": "0"
            },
            "measures": "[CD4+ median, CD4+ IQR lower, CD4+ IQR upper]",
            "outcomes": "[111, 31, 279]"
        },
        {
            "subject": {
                "study_type": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                "population": "newly diagnosed HIV patients",
                "hiv1_genotype": "CRF07_BC",
                "patients": "254",
                "percentage": "8.9",
                "cd4_median": "250",
                "cd4_iqr_lower": "156",
                "cd4_iqr_upper": "377",
                "unadjusted_coefficient": "139",
                "unadjusted_ci_lower": "117",
                "unadjusted_ci_upper": "161",
                "unadjusted_p_value": "<0.001",
                "adjusted_coefficient": "113",
                "adjusted_ci_lower": "86",
                "adjusted_ci_upper": "140",
                "adjusted_p_value": "<0.001"
            },
            "measures": "[CD4+ median, CD4+ IQR lower, CD4+ IQR upper, Unadjusted Coefficient, Unadjusted 95% CI lower, Unadjusted 95% CI upper, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI lower, Adjusted 95% CI upper, Adjusted P]",
            "outcomes": "[250, 156, 377, 139, 117, 161, <0.001, 113, 86, 140, <0.001]"
        },
        {
            "subject": {
                "study_type": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                "population": "newly diagnosed HIV patients",
                "hiv1_genotype": "CRF08_BC",
                "patients": "728",
                "percentage": "25.6",
                "cd4_median": "205",
                "cd4_iqr_lower": "108",
                "cd4_iqr_upper": "327",
                "unadjusted_coefficient": "94",
                "unadjusted_ci_lower": "73",
                "unadjusted_ci_upper": "115",
                "unadjusted_p_value": "<0.001",
                "adjusted_coefficient": "80",
                "adjusted_ci_lower": "65",
                "adjusted_ci_upper": "95",
                "adjusted_p_value": "<0.001"
            },
            "measures": "[CD4+ median, CD4+ IQR lower, CD4+ IQR upper, Unadjusted Coefficient, Unadjusted 95% CI lower, Unadjusted 95% CI upper, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI lower, Adjusted 95% CI upper, Adjusted P]",
            "outcomes": "[205, 108, 327, 94, 73, 115, <0.001, 80, 65, 95, <0.001]"
        },
        {
            "subject": {
                "study_type": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                "population": "newly diagnosed HIV patients",
                "hiv1_genotype": "Others",
                "patients": "176",
                "percentage": "6.2",
                "cd4_median": "198",
                "cd4_iqr_lower": "89",
                "cd4_iqr_upper": "355",
                "unadjusted_coefficient": "87",
                "unadjusted_ci_lower": "46",
                "unadjusted_ci_upper": "128",
                "unadjusted_p_value": "<0.001",
                "adjusted_coefficient": "72",
                "adjusted_ci_lower": "37",
                "adjusted_ci_upper": "107",
                "adjusted_p_value": "<0.001"
            },
            "measures": "[CD4+ median, CD4+ IQR lower, CD4+ IQR upper, Unadjusted Coefficient, Unadjusted 95% CI lower, Unadjusted 95% CI upper, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI lower, Adjusted 95% CI upper, Adjusted P]",
            "outcomes": "[198, 89, 355, 87, 46, 128, <0.001, 72, 37, 107, <0.001]"
        },
        {
            "subject": {
                "study_type": "effects of HIV-1 genotype on baseline CD4+ cell counts",
                "population": "newly diagnosed HIV patients",
                "adjustment_factors": "age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
            }
        }
    ],
    "PMC7414801_2": [
        {
            "subject": {
                "group": "As-randomized",
                "total participants": "382",
                "measurement": "HIV VL",
                "time point": "HIV detection visit",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[381, 100]"
        },
        {
            "subject": {
                "group": "As-randomized",
                "total participants": "382",
                "measurement": "HIV VL",
                "time point": "M3",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[114, 30]"
        },
        {
            "subject": {
                "group": "As-randomized",
                "total participants": "382",
                "measurement": "HIV VL",
                "time point": "M6",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[73, 19]"
        },
        {
            "subject": {
                "group": "As-randomized",
                "total participants": "382",
                "measurement": "HIV VL",
                "time point": "M9",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[43, 11]"
        },
        {
            "subject": {
                "group": "As-randomized",
                "total participants": "382",
                "measurement": "HIV VL",
                "time point": "M12",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[26, 7]"
        },
        {
            "subject": {
                "group": "As-randomized",
                "total participants": "382",
                "measurement": "HIV VL",
                "time point": "M15",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[17, 4]"
        },
        {
            "subject": {
                "group": "As-randomized",
                "total participants": "382",
                "measurement": "CD4",
                "time point": "HIV detection visit",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[382, 100]"
        },
        {
            "subject": {
                "group": "As-randomized",
                "total participants": "382",
                "measurement": "CD4",
                "time point": "M3",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[115, 30]"
        },
        {
            "subject": {
                "group": "As-randomized",
                "total participants": "382",
                "measurement": "CD4",
                "time point": "M6",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[73, 19]"
        },
        {
            "subject": {
                "group": "As-randomized",
                "total participants": "382",
                "measurement": "CD4",
                "time point": "M9",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[44, 12]"
        },
        {
            "subject": {
                "group": "As-randomized",
                "total participants": "382",
                "measurement": "CD4",
                "time point": "M12",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[26, 7]"
        },
        {
            "subject": {
                "group": "As-randomized",
                "total participants": "382",
                "measurement": "CD4",
                "time point": "M15",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[17, 4]"
        },
        {
            "subject": {
                "group": "Continuous use",
                "total participants": "331",
                "measurement": "HIV VL",
                "time point": "HIV detection visit",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[330, 100]"
        },
        {
            "subject": {
                "group": "Continuous use",
                "total participants": "331",
                "measurement": "HIV VL",
                "time point": "M3",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[99, 30]"
        },
        {
            "subject": {
                "group": "Continuous use",
                "total participants": "331",
                "measurement": "HIV VL",
                "time point": "M6",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[65, 20]"
        },
        {
            "subject": {
                "group": "Continuous use",
                "total participants": "331",
                "measurement": "HIV VL",
                "time point": "M9",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[40, 12]"
        },
        {
            "subject": {
                "group": "Continuous use",
                "total participants": "331",
                "measurement": "HIV VL",
                "time point": "M12",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[25, 8]"
        },
        {
            "subject": {
                "group": "Continuous use",
                "total participants": "331",
                "measurement": "HIV VL",
                "time point": "M15",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[14, 4]"
        },
        {
            "subject": {
                "group": "Continuous use",
                "total participants": "331",
                "measurement": "CD4",
                "time point": "HIV detection visit",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[331, 100]"
        },
        {
            "subject": {
                "group": "Continuous use",
                "total participants": "331",
                "measurement": "CD4",
                "time point": "M3",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[99, 30]"
        },
        {
            "subject": {
                "group": "Continuous use",
                "total participants": "331",
                "measurement": "CD4",
                "time point": "M6",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[64, 19]"
        },
        {
            "subject": {
                "group": "Continuous use",
                "total participants": "331",
                "measurement": "CD4",
                "time point": "M9",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[40, 12]"
        },
        {
            "subject": {
                "group": "Continuous use",
                "total participants": "331",
                "measurement": "CD4",
                "time point": "M12",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[25, 8]"
        },
        {
            "subject": {
                "group": "Continuous use",
                "total participants": "331",
                "measurement": "CD4",
                "time point": "M15",
                "footnote": "Excludes women infected at baseline and visits following ART initiation"
            },
            "measures": "[number of participants, percentage]",
            "outcomes": "[14, 4]"
        }
    ],
    "PMC11437459_2": [
        {
            "subject": {
                "combination therapy": "Atripla",
                "approval date": "2006",
                "TDF": "present",
                "TAF": "absent",
                "emtricitabine (FTC)": "present",
                "efavirenz (EFV)": "present",
                "rilpivirine (RPV)": "absent",
                "dolutegravir (DTG)": "absent",
                "elvitegravir (EVG)": "absent",
                "cobicistat (COBI)": "absent",
                "abacavir (ABC)": "absent",
                "lamivudine (3TC)": "absent"
            }
        },
        {
            "subject": {
                "combination therapy": "Complera",
                "approval date": "2011",
                "TDF": "present",
                "TAF": "absent",
                "emtricitabine (FTC)": "present",
                "efavirenz (EFV)": "absent",
                "rilpivirine (RPV)": "present",
                "dolutegravir (DTG)": "absent",
                "elvitegravir (EVG)": "absent",
                "cobicistat (COBI)": "absent",
                "abacavir (ABC)": "absent",
                "lamivudine (3TC)": "absent"
            }
        },
        {
            "subject": {
                "combination therapy": "Odefsey",
                "approval date": "2016",
                "TDF": "absent",
                "TAF": "present",
                "emtricitabine (FTC)": "present",
                "efavirenz (EFV)": "absent",
                "rilpivirine (RPV)": "present",
                "dolutegravir (DTG)": "absent",
                "elvitegravir (EVG)": "absent",
                "cobicistat (COBI)": "absent",
                "abacavir (ABC)": "absent",
                "lamivudine (3TC)": "absent"
            }
        },
        {
            "subject": {
                "combination therapy": "Stribild",
                "approval date": "2012",
                "TDF": "present",
                "TAF": "absent",
                "emtricitabine (FTC)": "present",
                "efavirenz (EFV)": "absent",
                "rilpivirine (RPV)": "absent",
                "dolutegravir (DTG)": "absent",
                "elvitegravir (EVG)": "present",
                "cobicistat (COBI)": "present",
                "abacavir (ABC)": "absent",
                "lamivudine (3TC)": "absent"
            }
        },
        {
            "subject": {
                "combination therapy": "Genvoya",
                "approval date": "2015",
                "TDF": "absent",
                "TAF": "present",
                "emtricitabine (FTC)": "present",
                "efavirenz (EFV)": "absent",
                "rilpivirine (RPV)": "absent",
                "dolutegravir (DTG)": "absent",
                "elvitegravir (EVG)": "present",
                "cobicistat (COBI)": "present",
                "abacavir (ABC)": "absent",
                "lamivudine (3TC)": "absent"
            }
        },
        {
            "subject": {
                "combination therapy": "Triumeq",
                "approval date": "2014",
                "TDF": "absent",
                "TAF": "absent",
                "emtricitabine (FTC)": "absent",
                "efavirenz (EFV)": "absent",
                "rilpivirine (RPV)": "absent",
                "dolutegravir (DTG)": "present",
                "elvitegravir (EVG)": "absent",
                "cobicistat (COBI)": "absent",
                "abacavir (ABC)": "present",
                "lamivudine (3TC)": "present"
            }
        },
        {
            "subject": {
                "combination therapy": "Dovato",
                "approval date": "2019",
                "TDF": "absent",
                "TAF": "absent",
                "emtricitabine (FTC)": "absent",
                "efavirenz (EFV)": "absent",
                "rilpivirine (RPV)": "absent",
                "dolutegravir (DTG)": "present",
                "elvitegravir (EVG)": "absent",
                "cobicistat (COBI)": "absent",
                "abacavir (ABC)": "absent",
                "lamivudine (3TC)": "present"
            }
        }
    ],
    "PMC9624454_2": [
        {
            "subject": {
                "group": "All children",
                "sample size": "1024"
            },
            "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
            "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
        },
        {
            "subject": {
                "group": "HIV unexposed",
                "sample size": "872"
            },
            "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
            "outcomes": "[253 (29.0), 45 (5.2), 2.3 (1.9\u20132.7)]"
        },
        {
            "subject": {
                "group": "HIV exposed",
                "sample size": "118",
                "note": "includes 6 children who were HIV exposed but whose HIV infection status was unknown"
            },
            "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics, P value for CMV Viremia, P value for CMV Viremia \u2264 1000 IU/mL, P value for log10 CMV IU/mL]",
            "outcomes": "[45 (38.1), 10 (8.5), 2.4 (2.0\u20132.9), 0.061, 0.18, 0.24]"
        },
        {
            "subject": {
                "group": "HIV exposed uninfected",
                "sample size": "97"
            },
            "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics, P value for CMV Viremia, P value for CMV Viremia \u2264 1000 IU/mL, P value for log10 CMV IU/mL]",
            "outcomes": "[36 (37.1), 6 (6.2), 2.4 (1.9\u20132.7), 0.088, 0.56, 0.74]"
        },
        {
            "subject": {
                "group": "HIV infected",
                "sample size": "15"
            },
            "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics, P value for CMV Viremia, P value for CMV Viremia \u2264 1000 IU/mL, P value for log10 CMV IU/mL]",
            "outcomes": "[6 (40.0), 3 (20.0), 3.2 (2.6\u20135.3), 0.39, 0.015, 0.012]"
        },
        {
            "subject": {
                "comparison method for CMV detection": "\u03c7\u00b2 test",
                "comparison group for CMV detection": "HIV-unexposed children"
            }
        },
        {
            "subject": {
                "comparison method for CMV detection \u2264 1000 IU/mL": "\u03c7\u00b2 test",
                "comparison group for CMV detection \u2264 1000 IU/mL": "HIV-unexposed children"
            }
        },
        {
            "subject": {
                "comparison method for CMV viral load distribution": "Wilcoxon rank-sum test",
                "comparison group for CMV viral load distribution": "HIV-unexposed children"
            }
        },
        {
            "subject": {
                "study population": "hospitalized children",
                "stratification factors": "HIV exposure, HIV infection"
            }
        },
        {
            "subject": {
                "CMV detection at hospital discharge": "314 children",
                "percentage of children with detectable CMV viremia at hospital discharge": "31%",
                "percentage of children with CMV levels \u2264 1000 IU/mL at hospital discharge": "5.8%"
            }
        }
    ],
    "PMC4549947_4": [
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "cognitive domain": "executive function",
                "group": "females"
            },
            "measures": "[odds ratio]",
            "outcomes": "[1.3]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "cognitive domain": "executive function",
                "group": "males"
            },
            "measures": "[odds ratio, 95% CI lower bound, 95% CI upper bound, p-value]",
            "outcomes": "[3.5, 1.5, 5.5, 0.008]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "cognitive domain": "executive function",
                "group": "hispanics"
            },
            "measures": "[odds ratio]",
            "outcomes": "[2.6]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "cognitive domain": "executive function",
                "group": "african american"
            },
            "measures": "[odds ratio, 95% CI lower bound, 95% CI upper bound, p-value]",
            "outcomes": "[3.1, 2.3, 3.5, 0.01]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "cognitive domain": "executive function",
                "group": "alcohol use"
            },
            "measures": "[odds ratio]",
            "outcomes": "[2.6]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "cognitive domain": "executive function",
                "comparison": "gender"
            },
            "measures": "[p-interaction]",
            "outcomes": "[0.35]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "cognitive domain": "executive function",
                "comparison": "race/ethnicity"
            },
            "measures": "[p-interaction]",
            "outcomes": "[0.05]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "cognitive domain": "cognitive flexibility",
                "group": "females"
            },
            "measures": "[odds ratio]",
            "outcomes": "[0.9]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "cognitive domain": "cognitive flexibility",
                "group": "males"
            },
            "measures": "[odds ratio, 95% CI lower bound, 95% CI upper bound, p-value]",
            "outcomes": "[1.8, 1.2, 2.9, 0.01]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "cognitive domain": "cognitive flexibility",
                "group": "hispanics"
            },
            "measures": "[odds ratio]",
            "outcomes": "[1.9]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "cognitive domain": "cognitive flexibility",
                "group": "african american"
            },
            "measures": "[odds ratio]",
            "outcomes": "[1.5]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "cognitive domain": "cognitive flexibility",
                "group": "alcohol use"
            },
            "measures": "[odds ratio, 95% CI lower bound, 95% CI upper bound, p-value]",
            "outcomes": "[1.6, 1.4, 2.4, 0.03]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "cognitive domain": "cognitive flexibility",
                "comparison": "gender"
            },
            "measures": "[p-interaction]",
            "outcomes": "[0.013]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "cognitive domain": "cognitive flexibility",
                "comparison": "race/ethnicity"
            },
            "measures": "[p-interaction]",
            "outcomes": "[0.72]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "cognitive domain": "cognitive flexibility",
                "comparison": "alcohol use"
            },
            "measures": "[p-interaction]",
            "outcomes": "[0.32]"
        }
    ],
    "PMC6694514_3": [
        {
            "subject": {
                "study": "REMoxTB trial",
                "population": "matched population",
                "adverse event grade": "grade 3 or 4",
                "adverse event SOC": "Hepatobiliary disorders",
                "HIV status": "HIV-positive"
            },
            "measures": "[number of adverse events, percentage of total grade 3+ events]",
            "outcomes": "[12, 30.0%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "population": "matched population",
                "adverse event grade": "grade 3 or 4",
                "adverse event SOC": "Hepatobiliary disorders",
                "HIV status": "HIV-negative"
            },
            "measures": "[number of adverse events, percentage of total grade 3+ events]",
            "outcomes": "[15, 25.0%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "population": "matched population",
                "adverse event grade": "grade 3 or 4",
                "adverse event SOC": "Respiratory and thoracic disorders",
                "HIV status": "HIV-positive"
            },
            "measures": "[number of adverse events, percentage of total grade 3+ events]",
            "outcomes": "[7, 17.5%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "population": "matched population",
                "adverse event grade": "grade 3 or 4",
                "adverse event SOC": "Respiratory and thoracic disorders",
                "HIV status": "HIV-negative"
            },
            "measures": "[number of adverse events, percentage of total grade 3+ events]",
            "outcomes": "[13, 21.7%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "population": "matched population",
                "adverse event grade": "grade 3 or 4",
                "adverse event SOC": "Blood and lymphatic disorders",
                "HIV status": "HIV-positive"
            },
            "measures": "[number of adverse events, percentage of total grade 3+ events]",
            "outcomes": "[6, 15.0%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "population": "matched population",
                "adverse event grade": "grade 3 or 4",
                "adverse event SOC": "Blood and lymphatic disorders",
                "HIV status": "HIV-negative"
            },
            "measures": "[number of adverse events, percentage of total grade 3+ events]",
            "outcomes": "[10, 16.7%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "population": "matched population",
                "adverse event grade": "grade 3 or 4",
                "adverse event SOC": "Infections and infestations",
                "HIV status": "HIV-positive"
            },
            "measures": "[number of adverse events, percentage of total grade 3+ events]",
            "outcomes": "[3, 7.5%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "population": "matched population",
                "adverse event grade": "grade 3 or 4",
                "adverse event SOC": "Infections and infestations",
                "HIV status": "HIV-negative"
            },
            "measures": "[number of adverse events, percentage of total grade 3+ events]",
            "outcomes": "[5, 8.3%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "population": "matched population",
                "adverse event grade": "grade 3 or 4",
                "adverse event SOC": "Metabolism and nutrition disorders",
                "HIV status": "HIV-positive"
            },
            "measures": "[number of adverse events, percentage of total grade 3+ events]",
            "outcomes": "[3, 7.5%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "population": "matched population",
                "adverse event grade": "grade 3 or 4",
                "adverse event SOC": "Metabolism and nutrition disorders",
                "HIV status": "HIV-negative"
            },
            "measures": "[number of adverse events, percentage of total grade 3+ events]",
            "outcomes": "[4, 6.7%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "population": "matched population",
                "adverse event grade": "grade 3 or 4",
                "adverse event SOC": "Other",
                "HIV status": "HIV-positive"
            },
            "measures": "[number of adverse events, percentage of total grade 3+ events]",
            "outcomes": "[9, 17.5%]"
        },
        {
            "subject": {
                "study": "REMoxTB trial",
                "population": "matched population",
                "adverse event grade": "grade 3 or 4",
                "adverse event SOC": "Other",
                "HIV status": "HIV-negative"
            },
            "measures": "[number of adverse events, percentage of total grade 3+ events]",
            "outcomes": "[13, 16.7%]"
        }
    ],
    "PMC6937831_2": [
        {
            "subject": {
                "death_category": "Non-AIDS-Related Death (NARD)",
                "subcategory": "Cancer",
                "number_of_deaths": "6",
                "percentage_of_deaths": "4%"
            }
        },
        {
            "subject": {
                "death_category": "Non-AIDS-Related Death (NARD)",
                "subcategory": "Other diseases",
                "number_of_deaths": "10",
                "percentage_of_deaths": "8%"
            }
        },
        {
            "subject": {
                "death_category": "Non-AIDS-Related Death (NARD)",
                "subcategory": "CVD",
                "number_of_deaths": "12",
                "percentage_of_deaths": "9%"
            }
        },
        {
            "subject": {
                "death_category": "Non-AIDS-Related Death (NARD)",
                "subcategory": "Hepatic/liver-related",
                "number_of_deaths": "34",
                "percentage_of_deaths": "24%"
            }
        },
        {
            "subject": {
                "death_category": "Non-AIDS-Related Death (NARD)",
                "subcategory": "External death",
                "number_of_deaths": "78",
                "percentage_of_deaths": "55%",
                "definition": "Sudden death, including accident, overdose, and suicide"
            }
        },
        {
            "subject": {
                "death_category": "AIDS-Related Death (ARD)",
                "subcategory": "Other diseases",
                "number_of_deaths": "2",
                "percentage_of_deaths": "1%",
                "categorization_criteria": "CD4 count lower than 200 cells/mm\u00b2 within 6-months prior to the date of death"
            }
        },
        {
            "subject": {
                "death_category": "AIDS-Related Death (ARD)",
                "subcategory": "Cancer",
                "number_of_deaths": "8",
                "percentage_of_deaths": "3%",
                "cancer_type": "AIDS-related cancers like cervical cancer"
            }
        },
        {
            "subject": {
                "death_category": "AIDS-Related Death (ARD)",
                "subcategory": "Opportunistic",
                "number_of_deaths": "241",
                "percentage_of_deaths": "96%"
            }
        }
    ],
    "PMC6949311_1": [
        {
            "subject": {
                "group": "HIV-1/AIDS patients",
                "sample size": "500",
                "gender": "male"
            },
            "measures": "[number of participants, percentage of participants]",
            "outcomes": "[326, 65.2%]"
        },
        {
            "subject": {
                "group": "HIV-1/AIDS patients",
                "sample size": "500",
                "gender": "female"
            },
            "measures": "[number of participants, percentage of participants]",
            "outcomes": "[174, 34.8%]"
        },
        {
            "subject": {
                "group": "HIV-1/AIDS patients",
                "sample size": "500"
            },
            "measures": "[mean age, standard deviation]",
            "outcomes": "[35.4, 7.9]"
        },
        {
            "subject": {
                "group": "healthy controls",
                "sample size": "500",
                "gender": "male"
            },
            "measures": "[number of participants, percentage of participants]",
            "outcomes": "[317, 63.4%]"
        },
        {
            "subject": {
                "group": "healthy controls",
                "sample size": "500",
                "gender": "female"
            },
            "measures": "[number of participants, percentage of participants]",
            "outcomes": "[183, 36.6%]"
        },
        {
            "subject": {
                "group": "healthy controls",
                "sample size": "500"
            },
            "measures": "[mean age, standard deviation]",
            "outcomes": "[36.2, 9.8]"
        },
        {
            "subject": {
                "comparison": "HIV-1/AIDS patients vs healthy controls",
                "variable": "gender"
            },
            "measures": "[P value]",
            "outcomes": "[0.553]"
        },
        {
            "subject": {
                "comparison": "HIV-1/AIDS patients vs healthy controls",
                "variable": "age"
            },
            "measures": "[P value]",
            "outcomes": "[0.180]"
        }
    ],
    "PMC8340029_2": [
        {
            "subject": {
                "analysis": "Effect of on-site PrEP access on HIV incidence",
                "group": "Before access",
                "time period": "Including study visits with on-site PrEP access",
                "adjustment": "None"
            },
            "measures": "[Number of infections/person-years, Incidence]",
            "outcomes": "[133/2860, 4.65%]"
        },
        {
            "subject": {
                "analysis": "Effect of on-site PrEP access on HIV incidence",
                "group": "After access",
                "time period": "Including study visits with on-site PrEP access",
                "adjustment": "Adjusted for study site and randomisation group"
            },
            "measures": "[Number of infections/person-years, Incidence, Adjusted incidence rate ratio (95% CI), p value]",
            "outcomes": "[12/556, 2.16%, 0.45 (0.25-0.81), 0.0076]"
        },
        {
            "subject": {
                "analysis": "Effect of on-site PrEP access on HIV incidence",
                "group": "After access",
                "time period": "Including study visits with on-site PrEP access",
                "adjustment": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
            },
            "measures": "[Adjusted incidence rate ratio (95% CI), p value]",
            "outcomes": "[0.45 (0.25-0.82), 0.0085]"
        },
        {
            "subject": {
                "analysis": "Effect of on-site PrEP access on HIV incidence",
                "group": "Before access",
                "time period": "180 days before versus 180 days after on-site PrEP access",
                "adjustment": "None"
            },
            "measures": "[Number of infections/person-years, Incidence]",
            "outcomes": "[46/919, 5.00%]"
        },
        {
            "subject": {
                "analysis": "Effect of on-site PrEP access on HIV incidence",
                "group": "After access",
                "time period": "180 days before versus 180 days after on-site PrEP access",
                "adjustment": "Adjusted for study site and randomisation group"
            },
            "measures": "[Number of infections/person-years, Incidence, Adjusted incidence rate ratio (95% CI), p value]",
            "outcomes": "[11/481, 2.29%, 0.44 (0.23-0.85), 0.015]"
        },
        {
            "subject": {
                "analysis": "Effect of on-site PrEP access on HIV incidence",
                "group": "After access",
                "time period": "180 days before versus 180 days after on-site PrEP access",
                "adjustment": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
            },
            "measures": "[Adjusted incidence rate ratio (95% CI), p value]",
            "outcomes": "[0.43 (0.22-0.83), 0.012]"
        }
    ],
    "PMC4731573_1": [
        {
            "subject": {
                "quantification": "HIV-2 (P-26) antigen",
                "donor": "No. 1",
                "HIV-1 measurement method": "Alliance HIV-1 p24 Antigen ELISA Kit",
                "HIV-1 kit manufacturer": "Perkin Elmer",
                "HIV-2 measurement method": "RETRO-TEK SIV p27 Antigen ELISA Kit",
                "HIV-2 kit manufacturer": "ZeptoMetrix"
            },
            "measures": "[HIV-1 p24, HIV-2 p26]",
            "outcomes": "[1909 pg/ml, 17683.965 pg/ml]"
        },
        {
            "subject": {
                "quantification": "HIV-2 (P-26) antigen",
                "donor": "No. 2",
                "HIV-1 measurement method": "Alliance HIV-1 p24 Antigen ELISA Kit",
                "HIV-1 kit manufacturer": "Perkin Elmer",
                "HIV-2 measurement method": "RETRO-TEK SIV p27 Antigen ELISA Kit",
                "HIV-2 kit manufacturer": "ZeptoMetrix"
            },
            "measures": "[HIV-1 p24, HIV-2 p26]",
            "outcomes": "[5649 pg/ml, 46071.77 pg/ml]"
        },
        {
            "subject": {
                "quantification": "HIV-2 (P-26) antigen",
                "donor": "No. 3",
                "HIV-1 measurement method": "Alliance HIV-1 p24 Antigen ELISA Kit",
                "HIV-1 kit manufacturer": "Perkin Elmer",
                "HIV-2 measurement method": "RETRO-TEK SIV p27 Antigen ELISA Kit",
                "HIV-2 kit manufacturer": "ZeptoMetrix"
            },
            "measures": "[HIV-1 p24, HIV-2 p26]",
            "outcomes": "[1803 pg/ml, 41414.58 pg/ml]"
        }
    ],
    "PMC9720390_1": [
        {
            "subject": {
                "characteristic": "number of participants",
                "PrEP doses": "one"
            },
            "measures": "[number of participants]",
            "outcomes": "[48]"
        },
        {
            "subject": {
                "characteristic": "number of participants",
                "PrEP doses": "two"
            },
            "measures": "[number of participants]",
            "outcomes": "[48]"
        },
        {
            "subject": {
                "characteristic": "number of participants",
                "PrEP doses": "no"
            },
            "measures": "[number of participants]",
            "outcomes": "[16]"
        },
        {
            "subject": {
                "characteristic": "median age",
                "PrEP doses": "one"
            },
            "measures": "[median age (years)]",
            "outcomes": "[19]"
        },
        {
            "subject": {
                "characteristic": "median age",
                "PrEP doses": "two"
            },
            "measures": "[median age (years)]",
            "outcomes": "[19]"
        },
        {
            "subject": {
                "characteristic": "median age",
                "PrEP doses": "no"
            },
            "measures": "[median age (years)]",
            "outcomes": "[19]"
        },
        {
            "subject": {
                "characteristic": "STI positivity",
                "PrEP doses": "one"
            },
            "measures": "[STI positivity]",
            "outcomes": "[2]"
        },
        {
            "subject": {
                "characteristic": "STI positivity",
                "PrEP doses": "two"
            },
            "measures": "[STI positivity]",
            "outcomes": "[4]"
        },
        {
            "subject": {
                "characteristic": "STI positivity",
                "PrEP doses": "no"
            },
            "measures": "[STI positivity]",
            "outcomes": "[0]"
        }
    ],
    "PMC11576434_2": [
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "analysis": "top ten most highly expressed TJ genes",
                "gene": "TRAF4",
                "gene name": "TNF receptor associated factor 4",
                "protein": "TRAF4",
                "protein function": "Adaptor protein involved in signal transduction and regulation of immune response, cell proliferation and apoptosis"
            }
        },
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "analysis": "top ten most highly expressed TJ genes",
                "gene": "RAP2B",
                "gene name": "RAP2B, member of RAS oncogene family",
                "protein": "RAP2B",
                "protein function": "Small GTPase involved in regulation of cell junction assembly and cell\u2013cell adhesion"
            }
        },
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "analysis": "top ten most highly expressed TJ genes",
                "gene": "CCND1",
                "gene name": "Cyclin D1",
                "protein": "Cyclin D1",
                "protein function": "Regulates cell cycle progression"
            }
        },
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "analysis": "top ten most highly expressed TJ genes",
                "gene": "NPHP4",
                "gene name": "Nephrocystin 4",
                "protein": "Nephrocystin 4",
                "protein function": "Functions in cilia and cell\u2013cell junctions; disruption leads to defects in epithelial architecture"
            }
        },
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "analysis": "top ten most highly expressed TJ genes",
                "gene": "TJAP1",
                "gene name": "Tight junction associated protein 1",
                "protein": "TJAP1",
                "protein function": "Scaffolding protein at tight junctions, involved in linking membrane proteins to cytoskeleton"
            }
        },
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "analysis": "top ten most highly expressed TJ genes",
                "gene": "ACTB",
                "gene name": "Actin beta",
                "protein": "\u03b2-actin",
                "protein function": "Structural protein involved in cell shape and motility"
            }
        },
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "analysis": "top ten most highly expressed TJ genes",
                "gene": "CRB3",
                "gene name": "Crumbs homolog 3",
                "protein": "CRB3",
                "protein function": "Maintains apical\u2013basal polarity in epithelial cells and tight junction integrity"
            }
        },
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "analysis": "top ten most highly expressed TJ genes",
                "gene": "PRKCZ",
                "gene name": "Protein kinase C zeta",
                "protein": "PKC\u03b6",
                "protein function": "Involved in TJ formation and maintenance via regulation of polarity complex proteins"
            }
        },
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "analysis": "top ten most highly expressed TJ genes",
                "gene": "CDH5",
                "gene name": "Cadherin 5",
                "protein": "VE-cadherin",
                "protein function": "Calcium-dependent adhesion protein involved in endothelial cell\u2013cell adhesion"
            }
        },
        {
            "subject": {
                "study": "CHAPS",
                "participants": "139",
                "analysis": "top ten most highly expressed TJ genes",
                "gene": "ATP7B",
                "gene name": "ATPase copper transporting beta",
                "protein": "ATP7B",
                "protein function": "Involved in copper transport and homeostasis; linked to oxidative stress regulation in epithelial cells"
            }
        }
    ],
    "PMC4486388_1": [
        {
            "subject": {
                "group": "1",
                "total participants": "10",
                "observed participants": "9",
                "mode of HIV-DNA delivery": "ID ZetaJet",
                "electroporation": "No",
                "left arm delivery": "1 inj 100 \u00b5l 0.3 mg DNA",
                "right arm delivery": "1 inj 100 \u00b5l 0.3 mg DNA",
                "left arm IM immunization": "1 inj HIV-MVA 10^8 pfu (1.0 ml)",
                "left arm delivery schedule": "weeks 0, 6, 12",
                "right arm delivery schedule": "weeks 0, 6, 12",
                "left arm IM immunization schedule": "weeks 24 and 40",
                "ampoule 1 content": "Env",
                "ampoule 2 content": "Gag, RTmut"
            }
        },
        {
            "subject": {
                "group": "1",
                "total participants": "2",
                "observed participants": "2",
                "mode of HIV-DNA delivery": "ID ZetaJet",
                "electroporation": "No",
                "left arm delivery": "1 inj 100 \u00b5l saline",
                "right arm delivery": "1 inj 100 \u00b5l saline",
                "left arm IM immunization": "1 inj 1.0 ml saline",
                "left arm delivery schedule": "weeks 0, 6, 12",
                "right arm delivery schedule": "weeks 0, 6, 12",
                "left arm IM immunization schedule": "weeks 24 and 40",
                "ampoule 1 content": "Env",
                "ampoule 2 content": "Gag, RTmut"
            }
        },
        {
            "subject": {
                "group": "2",
                "total participants": "10",
                "observed participants": "7",
                "mode of HIV-DNA delivery": "ID ZetaJet",
                "electroporation": "Yes",
                "left arm delivery": "1 inj 100 \u00b5l 0.3 mg DNA",
                "right arm delivery": "1 inj 100 \u00b5l 0.3 mg DNA",
                "left arm IM immunization": "1 inj HIV-MVA 10^8 pfu",
                "left arm delivery schedule": "weeks 0, 6, 12",
                "right arm delivery schedule": "weeks 0, 6, 12",
                "left arm IM immunization schedule": "weeks 24 and 40",
                "ampoule 1 content": "Env",
                "ampoule 2 content": "Gag, RTmut"
            }
        }
    ],
    "PMC8391097_3": [
        {
            "subject": {
                "study_type": "HIV Incidence Rate Estimates",
                "PrEP_status": "Overall",
                "exclusion_criteria": "Excludes individuals who were diagnosed with HIV during the eligibility assessment at PrEP linkage"
            },
            "measures": "[HIV_infections, total_individuals, total_follow_up, incidence_rate, incidence_rate_lower_CI, incidence_rate_upper_CI]",
            "outcomes": "[91, 13861, 26210, 0.35, 0.28, 0.43]"
        },
        {
            "subject": {
                "study_type": "HIV Incidence Rate Estimates",
                "PrEP_status": "Linked but not prescribed PrEP"
            },
            "measures": "[HIV_infections, total_individuals, total_follow_up, incidence_rate, incidence_rate_lower_CI, incidence_rate_upper_CI]",
            "outcomes": "[36, 3013, 4119, 0.87, 0.63, 1.21]"
        },
        {
            "subject": {
                "study_type": "HIV Incidence Rate Estimates",
                "PrEP_status": "Prescribed PrEP but did not initiate"
            },
            "measures": "[HIV_infections, total_individuals, total_follow_up, incidence_rate, incidence_rate_lower_CI, incidence_rate_upper_CI]",
            "outcomes": "[13, 811, 1226, 1.06, 0.62, 1.83]"
        },
        {
            "subject": {
                "study_type": "HIV Incidence Rate Estimates",
                "PrEP_status": "Discontinued but reinitiated PrEP"
            },
            "measures": "[HIV_infections, total_individuals, total_follow_up, incidence_rate, incidence_rate_lower_CI, incidence_rate_upper_CI]",
            "outcomes": "[4, 1082, 1420, 0.28, 0.11, 0.75]"
        },
        {
            "subject": {
                "study_type": "HIV Incidence Rate Estimates",
                "PrEP_status": "Discontinued and did not reinitiate PrEP"
            },
            "measures": "[HIV_infections, total_individuals, total_follow_up, incidence_rate, incidence_rate_lower_CI, incidence_rate_upper_CI]",
            "outcomes": "[38, 2108, 2973, 1.28, 0.93, 1.76]"
        },
        {
            "subject": {
                "study_type": "HIV Incidence Rate Estimates",
                "PrEP_status": "Persistent on PrEP",
                "definition": "Persistent on PrEP refers to individuals who initiated and remained on PrEP throughout follow-up",
                "CI_type": "One-sided 97.5% upper CI"
            },
            "measures": "[HIV_infections, total_individuals, total_follow_up, incidence_rate, incidence_rate_lower_CI, incidence_rate_upper_CI]",
            "outcomes": "[0, 5367, 9139, 0.00, 0.00, 0.04]"
        }
    ],
    "PMC4358901_1": [
        {
            "subject": {
                "virus_type": "HIV-1",
                "group": "M",
                "subtype": "A1"
            },
            "measures": "[number of genomes, number of patients, average length in nucleotides]",
            "outcomes": "[159, 134, 8500]"
        },
        {
            "subject": {
                "virus_type": "HIV-1",
                "group": "M",
                "subtype": "B"
            },
            "measures": "[number of genomes, number of patients, average length in nucleotides]",
            "outcomes": "[1425, 657, 8600]"
        },
        {
            "subject": {
                "virus_type": "HIV-1",
                "group": "M",
                "subtype": "C"
            },
            "measures": "[number of genomes, number of patients, average length in nucleotides]",
            "outcomes": "[554, 429, 8600]"
        },
        {
            "subject": {
                "virus_type": "HIV-1",
                "group": "M",
                "subtype": "D"
            },
            "measures": "[number of genomes, number of patients, average length in nucleotides]",
            "outcomes": "[65, 57, 8500]"
        },
        {
            "subject": {
                "virus_type": "HIV-1",
                "group": "M",
                "subtype": "F1"
            },
            "measures": "[number of genomes, number of patients, average length in nucleotides]",
            "outcomes": "[25, 22, 8500]"
        },
        {
            "subject": {
                "virus_type": "HIV-1",
                "group": "M",
                "subtype": "G"
            },
            "measures": "[number of genomes, number of patients, average length in nucleotides]",
            "outcomes": "[27, 23, 8600]"
        },
        {
            "subject": {
                "virus_type": "HIV-1",
                "group": "M",
                "subtype": "H"
            },
            "measures": "[number of genomes, number of patients, average length in nucleotides]",
            "outcomes": "[4, 4, 8500]"
        },
        {
            "subject": {
                "virus_type": "HIV-1",
                "group": "M",
                "subtype": "J"
            },
            "measures": "[number of genomes, number of patients, average length in nucleotides]",
            "outcomes": "[2, 2, 8500]"
        },
        {
            "subject": {
                "virus_type": "HIV-1",
                "group": "M",
                "subtype": "K"
            },
            "measures": "[number of genomes, number of patients, average length in nucleotides]",
            "outcomes": "[2, 2, 8500]"
        },
        {
            "subject": {
                "virus_type": "HIV-1",
                "group": "M",
                "subtype": "01_AE"
            },
            "measures": "[number of genomes, number of patients, average length in nucleotides]",
            "outcomes": "[581, 250, 8600]"
        },
        {
            "subject": {
                "virus_type": "HIV-1",
                "group": "M",
                "subtype": "02_AG"
            },
            "measures": "[number of genomes, number of patients, average length in nucleotides]",
            "outcomes": "[81, 71, 8600]"
        },
        {
            "subject": {
                "virus_type": "HIV-1",
                "group": "N"
            },
            "measures": "[number of genomes, number of patients, average length in nucleotides]",
            "outcomes": "[11, 9, 8600]"
        },
        {
            "subject": {
                "virus_type": "HIV-1",
                "group": "O"
            },
            "measures": "[number of genomes, number of patients, average length in nucleotides]",
            "outcomes": "[25, 22, 8600]"
        },
        {
            "subject": {
                "virus_type": "HIV-1",
                "group": "P"
            },
            "measures": "[number of genomes, number of patients, average length in nucleotides]",
            "outcomes": "[4, 2, 8500]"
        },
        {
            "subject": {
                "virus_type": "HIV-2",
                "group": "A"
            },
            "measures": "[number of genomes, number of patients, average length in nucleotides]",
            "outcomes": "[25, 16, 8600]"
        },
        {
            "subject": {
                "virus_type": "HIV-2",
                "group": "B"
            },
            "measures": "[number of genomes, number of patients, average length in nucleotides]",
            "outcomes": "[6, 5, 8500]"
        }
    ],
    "PMC8748440_2": [
        {
            "subject": {
                "analysis": "Univariable Cox regression",
                "gene": "ISG15",
                "statistical measure": "HR",
                "HR": "0.29",
                "HR 95% CI lower": "0.11",
                "HR 95% CI upper": "0.81"
            },
            "measures": "[p value]",
            "outcomes": "[0.0091]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression",
                "gene": "IFI6",
                "statistical measure": "HR",
                "HR": "0.18",
                "HR 95% CI lower": "0.037",
                "HR 95% CI upper": "0.86"
            },
            "measures": "[p value]",
            "outcomes": "[0.014]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression",
                "gene": "IFI44L",
                "statistical measure": "HR",
                "HR": "0.55",
                "HR 95% CI lower": "0.27",
                "HR 95% CI upper": "1.1"
            },
            "measures": "[p value]",
            "outcomes": "[0.083]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression",
                "gene": "IFI44",
                "statistical measure": "HR",
                "HR": "0.23",
                "HR 95% CI lower": "0.047",
                "HR 95% CI upper": "1.2"
            },
            "measures": "[p value]",
            "outcomes": "[0.045]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression",
                "gene": "IFIT1",
                "statistical measure": "HR",
                "HR": "0.37",
                "HR 95% CI lower": "0.12",
                "HR 95% CI upper": "1.1"
            },
            "measures": "[p value]",
            "outcomes": "[0.054]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression",
                "gene": "OAS3",
                "statistical measure": "HR",
                "HR": "0.52",
                "HR 95% CI lower": "0.22",
                "HR 95% CI upper": "1.3"
            },
            "measures": "[p value]",
            "outcomes": "[0.15]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression",
                "gene": "XAF1",
                "statistical measure": "HR",
                "HR": "0.3",
                "HR 95% CI lower": "0.1",
                "HR 95% CI upper": "0.92"
            },
            "measures": "[p value]",
            "outcomes": "[0.027]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression",
                "gene": "TRIM25",
                "statistical measure": "HR",
                "HR": "0.074",
                "HR 95% CI lower": "0.0068",
                "HR 95% CI upper": "0.8"
            },
            "measures": "[p value]",
            "outcomes": "[0.023]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression",
                "gene": "CMPK2",
                "statistical measure": "HR",
                "HR": "0.23",
                "HR 95% CI lower": "0.037",
                "HR 95% CI upper": "1.5"
            },
            "measures": "[p value]",
            "outcomes": "[0.074]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression",
                "gene": "RSAD2",
                "statistical measure": "HR",
                "HR": "0.2",
                "HR 95% CI lower": "0.041",
                "HR 95% CI upper": "0.99"
            },
            "measures": "[p value]",
            "outcomes": "[0.032]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression",
                "gene": "EIF2AK2",
                "statistical measure": "HR",
                "HR": "0.54",
                "HR 95% CI lower": "0.12",
                "HR 95% CI upper": "2.4"
            },
            "measures": "[p value]",
            "outcomes": "[0.42]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression",
                "gene": "USP18",
                "statistical measure": "HR",
                "HR": "0.23",
                "HR 95% CI lower": "0.062",
                "HR 95% CI upper": "0.84"
            },
            "measures": "[p value]",
            "outcomes": "[0.022]"
        },
        {
            "subject": {
                "analysis": "Univariable Cox regression",
                "gene": "HERC6",
                "statistical measure": "HR",
                "HR": "0.16",
                "HR 95% CI lower": "0.019",
                "HR 95% CI upper": "1.3"
            },
            "measures": "[p value]",
            "outcomes": "[0.057]"
        }
    ],
    "PMC7615197_2": [
        {
            "subject": {
                "population": "Intention-to-treat population",
                "treatment": "Dexamethasone",
                "control": "Placebo",
                "sample size treatment": "263",
                "sample size control": "257",
                "primary endpoint": "death from any cause over the first 12 months after randomization",
                "statistical model": "Cox proportional hazards regression"
            },
            "measures": "[number of deaths treatment, number of deaths control, hazard ratio, 95% CI lower, 95% CI upper, P value, test for proportional hazards]",
            "outcomes": "[116, 126, 0.85, 0.66, 1.10, 0.22, 0.36]"
        },
        {
            "subject": {
                "population": "Modified MRC grade I",
                "treatment": "Dexamethasone",
                "control": "Placebo",
                "sample size treatment": "99",
                "sample size control": "97",
                "primary endpoint": "death from any cause over the first 12 months after randomization",
                "statistical model": "Cox proportional hazards regression"
            },
            "measures": "[number of deaths treatment, number of deaths control, hazard ratio, 95% CI lower, 95% CI upper, P value, test for proportional hazards, P-value for heterogeneity]",
            "outcomes": "[22, 28, 0.72, 0.41, 1.25, 0.24, 0.15, 0.63]"
        },
        {
            "subject": {
                "population": "Modified MRC grade II",
                "treatment": "Dexamethasone",
                "control": "Placebo",
                "sample size treatment": "125",
                "sample size control": "126",
                "primary endpoint": "death from any cause over the first 12 months after randomization",
                "statistical model": "Cox proportional hazards regression"
            },
            "measures": "[number of deaths treatment, number of deaths control, hazard ratio, 95% CI lower, 95% CI upper, P value, test for proportional hazards, P-value for heterogeneity]",
            "outcomes": "[60, 68, 0.82, 0.58, 1.16, 0.27, 0.57, 0.63]"
        },
        {
            "subject": {
                "population": "Modified MRC grade III",
                "treatment": "Dexamethasone",
                "control": "Placebo",
                "sample size treatment": "39",
                "sample size control": "34",
                "primary endpoint": "death from any cause over the first 12 months after randomization",
                "statistical model": "Cox proportional hazards regression"
            },
            "measures": "[number of deaths treatment, number of deaths control, hazard ratio, 95% CI lower, 95% CI upper, P value, test for proportional hazards, P-value for heterogeneity]",
            "outcomes": "[34, 30, 1.11, 0.70, 1.77, 0.65, 0.89, 0.63]"
        }
    ],
    "PMC9008168_2": [
        {
            "subject": {
                "outcome": "BMI \u226525 kg/m\u00b2",
                "group": "Participants without HIV",
                "unadjusted incidence rate": "69.8 cases/1000 PY",
                "unadjusted incidence rate 95% CI": "54.7\u201389.0",
                "HR": "1.00",
                "HR 95% CI": "Reference",
                "total participants at risk": "2144",
                "total cases": "516"
            }
        },
        {
            "subject": {
                "outcome": "BMI \u226525 kg/m\u00b2",
                "group": "PLWH on non-TLD ART",
                "unadjusted incidence rate": "77.1 cases/1000 PY",
                "unadjusted incidence rate 95% CI": "69.8\u201385.2",
                "HR": "1.13",
                "HR 95% CI": "0.79\u20131.63",
                "total participants at risk": "2144",
                "total cases": "516"
            }
        },
        {
            "subject": {
                "outcome": "BMI \u226525 kg/m\u00b2",
                "group": "PLWH on TLD",
                "unadjusted incidence rate": "73.3 cases/1000 PY",
                "unadjusted incidence rate 95% CI": "54.0\u201399.6",
                "HR": "1.77",
                "HR 95% CI": "1.22\u20132.55",
                "total participants at risk": "2144",
                "total cases": "516"
            }
        },
        {
            "subject": {
                "outcome": "BMI \u226525 kg/m\u00b2",
                "group": "PLWH, ART na\u00efve",
                "unadjusted incidence rate": "37.7 cases/1000 PY",
                "unadjusted incidence rate 95% CI": "24.1\u201359.1",
                "HR": "0.43",
                "HR 95% CI": "0.27\u20130.70",
                "total participants at risk": "2144",
                "total cases": "516"
            }
        }
    ],
    "PMC10022814_1": [
        {
            "subject": {
                "design": "All-comers design",
                "primary objective": "Evaluate VE in population not on stable PrEP",
                "key secondary objective": "Evaluate VE among those not on PrEP at acquisition"
            }
        },
        {
            "subject": {
                "design": "1-Stage Run-In Design",
                "primary objective": "Evaluate VE in population declining or not adherent to PrEP at screening or after 1 stage of PrEP",
                "key secondary objective 1": "Evaluate VE among those not on PrEP at acquisition",
                "key secondary objective 2": "Evaluate PrEP effectiveness (PrEP vs. Placebo)",
                "key secondary objective 3": "Compare Vaccine vs. PrEP effectiveness"
            }
        },
        {
            "subject": {
                "design": "3-Stage Run-In Design",
                "primary objective": "Evaluate VE in population declining or not adherent to PrEP at screening or after 1, 2, or 3 stages of PrEP",
                "key secondary objective 1": "Evaluate VE among those not on PrEP at acquisition",
                "key secondary objective 2": "Evaluate PrEP effectiveness (PrEP vs. Placebo)",
                "key secondary objective 3": "Compare Vaccine vs. PrEP effectiveness"
            }
        },
        {
            "subject": {
                "design": "Decliners Design",
                "primary objective": "Evaluate VE in population declining PrEP at screening",
                "key secondary objective": "Evaluate VE among those not on PrEP at acquisition"
            }
        },
        {
            "subject": {
                "footnote a": "Addressed using retrospective assaying of stored blood to test for ARV drug levels"
            }
        },
        {
            "subject": {
                "footnote b": "Evaluable if designs continue to follow and collect HIV endpoint data on individuals who remain interested and adherent to PrEP after each run-in period"
            }
        }
    ],
    "PMC7644038_3": [
        {
            "subject": {
                "population": "Medicare beneficiaries",
                "age": "65",
                "year range": "2011-2016",
                "condition": "HIV",
                "health outcome": "Depression",
                "data type": "unadjusted"
            },
            "measures": "[prevalence]",
            "outcomes": "[24.3%]"
        },
        {
            "subject": {
                "population": "Medicare beneficiaries",
                "age": "65",
                "year range": "2011-2016",
                "condition": "No HIV",
                "health outcome": "Depression",
                "data type": "unadjusted"
            },
            "measures": "[prevalence]",
            "outcomes": "[6.2%]"
        },
        {
            "subject": {
                "population": "Medicare beneficiaries",
                "age": "65",
                "year range": "2011-2016",
                "health outcome": "Depression",
                "data type": "unadjusted",
                "comparison": "HIV vs No HIV",
                "statistical test": "chi-squared"
            },
            "measures": "[percent difference, significance level]",
            "outcomes": "[291.9%, p<0.001]"
        },
        {
            "subject": {
                "population": "Medicare beneficiaries",
                "age": "65 and above",
                "year": "2016",
                "condition": "HIV",
                "health outcome": "Depression",
                "analysis": "logistic regression",
                "controls": "age, race/ethnicity, sex, state, rural/urban residence, dual enrollment in Medicaid",
                "reference group": "White, urban, non-Medicaid enrolled males between the age of 65 and 74",
                "weighting": "probability weights based on HIV diagnosis",
                "multiple hypothesis testing correction": "Bonferroni",
                "confidence interval": "95%"
            },
            "measures": "[odds ratio, lower CI, upper CI]",
            "outcomes": "[2.29, 2.22, 2.35]"
        },
        {
            "subject": {
                "population": "Medicare beneficiaries",
                "age": "65",
                "year range": "2011-2016",
                "condition": "HIV",
                "health outcome": "Chronic kidney disease",
                "data type": "unadjusted"
            },
            "measures": "[prevalence]",
            "outcomes": "[46.2%]"
        },
        {
            "subject": {
                "population": "Medicare beneficiaries",
                "age": "65",
                "year range": "2011-2016",
                "condition": "No HIV",
                "health outcome": "Chronic kidney disease",
                "data type": "unadjusted"
            },
            "measures": "[prevalence]",
            "outcomes": "[18.9%]"
        },
        {
            "subject": {
                "population": "Medicare beneficiaries",
                "age": "65",
                "year range": "2011-2016",
                "health outcome": "Chronic kidney disease",
                "data type": "unadjusted",
                "comparison": "HIV vs No HIV",
                "statistical test": "chi-squared"
            },
            "measures": "[percent difference, significance level]",
            "outcomes": "[144.4%, p<0.001]"
        },
        {
            "subject": {
                "population": "Medicare beneficiaries",
                "age": "65 and above",
                "year": "2016",
                "condition": "HIV",
                "health outcome": "Chronic kidney disease",
                "analysis": "logistic regression",
                "controls": "age, race/ethnicity, sex, state, rural/urban residence, dual enrollment in Medicaid",
                "reference group": "White, urban, non-Medicaid enrolled males between the age of 65 and 74",
                "weighting": "probability weights based on HIV diagnosis",
                "multiple hypothesis testing correction": "Bonferroni",
                "confidence interval": "95%"
            },
            "measures": "[odds ratio, lower CI, upper CI]",
            "outcomes": "[1.92, 1.88, 1.97]"
        }
    ],
    "PMC6033411_2": [
        {
            "subject": {
                "characteristic": "age",
                "age group": "15 and younger",
                "total participants": "200",
                "participants in group": "69",
                "percentage in group": "34.5%",
                "clustered participants": "22",
                "percentage clustered": "37.3%",
                "odds ratio": "1.0",
                "reference group": "yes",
                "genetic distance threshold": "4.5%"
            },
            "measures": "[number of clustered, total number, odds ratio]",
            "outcomes": "[22, 69, 1.0]"
        },
        {
            "subject": {
                "characteristic": "age",
                "age group": "16",
                "total participants": "200",
                "participants in group": "46",
                "percentage in group": "23%",
                "clustered participants": "13",
                "percentage clustered": "22%",
                "odds ratio": "0.84",
                "confidence interval": "0.36\u20131.89",
                "p-value": "0.67",
                "genetic distance threshold": "4.5%"
            },
            "measures": "[number of clustered, total number, odds ratio, p-value]",
            "outcomes": "[13, 46, 0.84, 0.67]"
        },
        {
            "subject": {
                "characteristic": "age",
                "age group": "17+",
                "total participants": "200",
                "participants in group": "85",
                "percentage in group": "42.5%",
                "clustered participants": "24",
                "percentage clustered": "40.7%",
                "odds ratio": "0.87",
                "confidence interval": "0.43\u20131.76",
                "p-value": "0.69",
                "genetic distance threshold": "4.5%"
            },
            "measures": "[number of clustered, total number, odds ratio, p-value]",
            "outcomes": "[24, 85, 0.87, 0.69]"
        },
        {
            "subject": {
                "characteristic": "school grade",
                "grade group": "8\u20139",
                "total participants": "200",
                "participants in group": "90",
                "percentage in group": "45%",
                "clustered participants": "30",
                "percentage clustered": "50.8%",
                "odds ratio": "1.0",
                "reference group": "yes",
                "genetic distance threshold": "4.5%"
            },
            "measures": "[number of clustered, total number, odds ratio]",
            "outcomes": "[30, 90, 1.0]"
        },
        {
            "subject": {
                "characteristic": "school grade",
                "grade group": "10\u201312",
                "total participants": "200",
                "participants in group": "110",
                "percentage in group": "55%",
                "clustered participants": "29",
                "percentage clustered": "49.2%",
                "odds ratio": "0.8",
                "confidence interval": "0.43\u20131.52",
                "p-value": "0.5",
                "genetic distance threshold": "4.5%"
            },
            "measures": "[number of clustered, total number, odds ratio, p-value]",
            "outcomes": "[29, 110, 0.8, 0.5]"
        },
        {
            "subject": {
                "characteristic": "household income",
                "income group": "<999 R",
                "total participants": "200",
                "participants in group": "61",
                "percentage in group": "30.5%",
                "clustered participants": "22",
                "percentage clustered": "37.3%",
                "odds ratio": "1.0",
                "reference group": "yes",
                "genetic distance threshold": "4.5%"
            },
            "measures": "[number of clustered, total number, odds ratio]",
            "outcomes": "[22, 61, 1.0]"
        },
        {
            "subject": {
                "characteristic": "household income",
                "income group": "10,000\u201399,000 R",
                "total participants": "200",
                "participants in group": "112",
                "percentage in group": "56%",
                "clustered participants": "27",
                "percentage clustered": "45.8%",
                "odds ratio": "0.56",
                "confidence interval": "0.29\u20131.11",
                "p-value": "0.1",
                "genetic distance threshold": "4.5%"
            },
            "measures": "[number of clustered, total number, odds ratio, p-value]",
            "outcomes": "[27, 112, 0.56, 0.1]"
        },
        {
            "subject": {
                "characteristic": "household income",
                "income group": ">100,000 R",
                "total participants": "200",
                "participants in group": "27",
                "percentage in group": "12.5%",
                "clustered participants": "10",
                "percentage clustered": "16.9%",
                "odds ratio": "1.04",
                "confidence interval": "0.39\u20132.65",
                "p-value": "0.93",
                "genetic distance threshold": "4.5%"
            },
            "measures": "[number of clustered, total number, odds ratio, p-value]",
            "outcomes": "[10, 27, 1.04, 0.93]"
        },
        {
            "subject": {
                "characteristic": "CD4 cell count",
                "CD4 count group": ">500 cells/mm3",
                "total participants": "200",
                "participants in group": "92",
                "percentage in group": "46%",
                "clustered participants": "30",
                "percentage clustered": "50.9%",
                "odds ratio": "1.0",
                "reference group": "yes",
                "genetic distance threshold": "4.5%"
            },
            "measures": "[number of clustered, total number, odds ratio]",
            "outcomes": "[30, 92, 1.0]"
        },
        {
            "subject": {
                "characteristic": "CD4 cell count",
                "CD4 count group": "\u2264500 cells/mm3",
                "total participants": "200",
                "participants in group": "75",
                "percentage in group": "37.5%",
                "clustered participants": "19",
                "percentage clustered": "32.2%",
                "odds ratio": "0.70",
                "confidence interval": "0.35\u20131.37",
                "p-value": "0.31",
                "genetic distance threshold": "4.5%"
            },
            "measures": "[number of clustered, total number, odds ratio, p-value]",
            "outcomes": "[19, 75, 0.70, 0.31]"
        },
        {
            "subject": {
                "characteristic": "CD4 cell count",
                "CD4 count group": "\u2264250 cells/mm3",
                "total participants": "200",
                "participants in group": "15",
                "percentage in group": "7.5%",
                "clustered participants": "4",
                "percentage clustered": "6.8%",
                "odds ratio": "0.75",
                "confidence interval": "0.2\u20132.4",
                "p-value": "0.65",
                "genetic distance threshold": "4.5%"
            },
            "measures": "[number of clustered, total number, odds ratio, p-value]",
            "outcomes": "[4, 15, 0.75, 0.65]"
        },
        {
            "subject": {
                "characteristic": "major drug resistance mutation",
                "mutation status": "no",
                "total participants": "200",
                "participants in group": "180",
                "percentage in group": "90%",
                "clustered participants": "55",
                "percentage clustered": "93.2%",
                "odds ratio": "1.0",
                "reference group": "yes",
                "genetic distance threshold": "4.5%"
            },
            "measures": "[number of clustered, total number, odds ratio]",
            "outcomes": "[55, 180, 1.0]"
        },
        {
            "subject": {
                "characteristic": "major drug resistance mutation",
                "mutation status": "yes",
                "total participants": "200",
                "participants in group": "20",
                "percentage in group": "10%",
                "clustered participants": "4",
                "percentage clustered": "6.8%",
                "odds ratio": "0.57",
                "confidence interval": "0.16\u20131.63",
                "p-value": "0.33",
                "genetic distance threshold": "4.5%"
            },
            "measures": "[number of clustered, total number, odds ratio, p-value]",
            "outcomes": "[4, 20, 0.57, 0.33]"
        },
        {
            "subject": {
                "characteristic": "HSV-2 infection",
                "HSV-2 status": "no",
                "total participants": "200",
                "participants in group": "90",
                "percentage in group": "45%",
                "clustered participants": "25",
                "percentage clustered": "42.4%",
                "odds ratio": "1.0",
                "reference group": "yes",
                "genetic distance threshold": "4.5%"
            },
            "measures": "[number of clustered, total number, odds ratio]",
            "outcomes": "[25, 90, 1.0]"
        },
        {
            "subject": {
                "characteristic": "HSV-2 infection",
                "HSV-2 status": "yes",
                "total participants": "200",
                "participants in group": "69",
                "percentage in group": "34.5%",
                "clustered participants": "23",
                "percentage clustered": "39%",
                "odds ratio": "1.3",
                "confidence interval": "0.65\u20132.57",
                "p-value": "0.45",
                "genetic distance threshold": "4.5%"
            },
            "measures": "[number of clustered, total number, odds ratio, p-value]",
            "outcomes": "[23, 69, 1.3, 0.45]"
        },
        {
            "subject": {
                "characteristic": "ever pregnant",
                "pregnancy status": "no",
                "total participants": "200",
                "participants in group": "122",
                "percentage in group": "61%",
                "clustered participants": "37",
                "percentage clustered": "62.7%",
                "odds ratio": "1.0",
                "reference group": "yes",
                "genetic distance threshold": "4.5%"
            },
            "measures": "[number of clustered, total number, odds ratio]",
            "outcomes": "[37, 122, 1.0]"
        },
        {
            "subject": {
                "characteristic": "ever pregnant",
                "pregnancy status": "yes",
                "total participants": "200",
                "participants in group": "49",
                "percentage in group": "24.5%",
                "clustered participants": "15",
                "percentage clustered": "25.4%",
                "odds ratio": "1.01",
                "confidence interval": "0.48\u20132.06",
                "p-value": "0.971",
                "genetic distance threshold": "4.5%"
            },
            "measures": "[number of clustered, total number, odds ratio, p-value]",
            "outcomes": "[15, 49, 1.01, 0.971]"
        }
    ]
}